A retrospective observational study of over 28,000 polycythemia vera (PV) patients in the USA has just been published in the January 2023 edition of the Annals of Hematology.

The main finding suggests that in the US, currently available PV treatments may not be used to full advantage.
Conclusions recommend “more detailed exploration in other studies, but these data do indicate substantial collective reliance on an established therapy, phlebotomy, despite a low percentage of patients achieving guideline-recommended results in hematocrit control, and 8% of low-risk and 20% of high-risk patients experiencing thrombotic events despite access to all available treatment options.”

The full article is available HERE.